Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Gamma Communications trading shifts to Main Market

(Sharecast News) - Gamma Communications announced the successful admission of its ordinary shares to the Main Market of the London Stock Exchange on Friday, marking a significant milestone in the company's development. The company confirmed that trading of its shares on AIM had now been cancelled.

Its move followed an earlier announcement on 25 April, and saw Gamma's shares admitted to the Equity Shares (Commercial Companies) category of the FCA's Official List.

The company confirmed that no new shares or other securities were issued in connection with the admission.

Gamma, a provider of technology-based communication services across Europe, said its ordinary shares would continue to trade under the existing ISIN GB00BQS10J50 and ticker symbol GAMA.

"Since our admission to AIM in 2014, we've delivered strong financial and operational growth, transitioning from a UK-based company into a leading European business," said chief executive officer Andrew Belshaw.

"We would like to extend our thanks to our dedicated investors, employees, customers, partners, and advisers for their continued support in helping us reach this important milestone.

"As an established business with a strong track record for high recurring revenue, strong margins, and high cash generation, we believe the move to the Main Market will best support the delivery of our long-term strategy and offer the appropriate listing for a company of our scale and ambition."

At 1213 BST, shares in Gamma Communications were up 2.02% at 1,356.88p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.